Page 124 - Livre électronique du congrès national de pneumologie 2022

patient a eu une bi lobectomie et un autre patient a department, Pavilion IV of Abderahman Mami
eu une pneumonectomie. En revanche, tous les pulmonology hospital, from 2014 to 2022. The gene
patients ont bénéficié d’un curage ganglionnaire. mutation research was performed on histological
Quatre patients (45,5% des cas) ont bénéficié de materiel of bronchial biopsy in patients with NSCLC.
chimiothérapie néoadjuvante, un seul patient a eu Sociodemographic information, clinical and
une chimiothérapie adjuvante et 18,2% ont eu une radiological features as well as blood test results
radiothérapie curative. Trois patients étaient perdus were collected from medical records.
de vue après six mois du traitement chirurgical et
pour le reste des patients, aucun décès n’a été noté RESULTS:
pendant la durée de suivi (49 ± 69 mois). Mutation research was performed for 13 patients.

CONCLUSION : Sex ratio was 1:5. The mean age was 57±13,07 years.
Ten patients with stage IV of adenocarcinoma had
Le profil épidémiologique et clinique des KBP molecular alterations. Epidermal growth factor
opérables est celui d’un patient de la soixantaine receptor (EGFR) mutation was found in 6 patients.
tabagique, ayant des symptômes exclusivement Anaplastic lymphoma kinase (ALK) translocation was
respiratoires le ramenant à consulter précocement. found in 3 patients. Proto-oncogene tyrosine-
La prise en charge thérapeutique rapide permet protein kinase-1 (ROS-1) rearrangement was found in 1
d’améliorer le pronostic vital de ces patients. patient. All of the patients underwent chemotherapy
followed by targeted therapy. Five patients have
P114. TARGETED THERAPY FOR NON-SMALL received Erlotinib ,two patients have received
CELL LUNG CARCINOMA : WHERE ARE WE? Osimertinib and four patients have received
Crizotinib. The mean time to diagnose gene
Jelassi.W1, Habouria.C1, Belloumi.N1, Bechouch.I1, Bejaoui.T1, mutation was 133,44 ± 123,39 days. The mean time to
Elfidha.S1, Chermiti.F1, Fenniche.S1 start targeted therapy was 50,89 ± 53,87 days. Six
patients had adverse effects. The most common
1PULMONOLOGY DEPARTMENT PAVILION IV, PULMONOLOGY
HOSPITAL ABDERRAHMAN MAMI, ARIANA, TUNISIA adverse effects were gastrointestinal and
cutaneous effects. One patient was diagnosed with

INTRODUCTION: retinal detachment induced by Crizotinib, an ALK-
tyrosine kinase inhibitor. Tumor progression after
The prognosis of non-small cell lung cancer (NSCLC) targeted therapy was found in three patients. The
has improved dramatically since the discovery of mean time to tumor progression was 3,89 ± 4,95
oncogenic molecular alterations that can be months. The mean overall survival was 17,37 ± 9,40
targeted by specific therapies such as tyrosine months. The mean progression free survival was 9,60
kinase inhibitors (TKI). Targeted therapy has become ± 10,75 months.
the key to improving overall survival while
decreasing the adverse effects of cancer treatment. CONCLUSION:
However, in Tunisia, access to these innovative This experience highlights the efficacity of targeted
therapies remains limited due to their high cost and therapy for providing clinical benefit in patients
lack of access to reimbursement by health insurance with adenocarcinoma and an improved
companies. progression-free survival and overall survival.

OBJECTIVE:
To describe our real-world experience of using
targeted therapy to treat patients with a mutant
adenocarcinoma of the lung.

METHODS:
We restrospectively screened 2442 patients with
confirmed lung carcinoma in the pulmonology

118 | P a ge